View Older Stories View More Recent Stories

Feb 26, 2021 04:05PM Horizon Therapeutics plc to Present at the Cowen and Company 41st Annual Health Care Conference
Feb 25, 2021 04:05PM Horizon Therapeutics plc Shines a Light on Rare Disease with the Launch of the #RAREis Photobooth to Benefit Make-A-Wish®
Feb 24, 2021 07:00AM Horizon Therapeutics plc Reports Record Fourth-Quarter and Full-Year 2020 Financial Results; Announces Full-Year 2021 Guidance
Feb 22, 2021 09:30AM New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Well Beyond Acute Disease into Chronic Phase
Feb 4, 2021 01:00AM Horizon Therapeutics plc Expands Medidata Partnership to Further Enhance Clinical Trial Efficiencies and Outcomes
Feb 4, 2021 12:58AM Dassault Systèmes: Horizon Therapeutics plc Expands Medidata Partnership to Further Enhance Clinical Trial Efficiencies and Outcomes
Feb 3, 2021 08:00AM Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2020 Financial Results and Host Webcast on Feb. 24, 2021
Feb 1, 2021 07:03AM Horizon Therapeutics (HZNP) to Acquire Viela Bio (VIE) for $53 Per Share in $3.05 Billion Deal
Feb 1, 2021 07:00AM Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio
Jan 11, 2021 07:04AM Horizon Therapeutics (HZNP) Provides Preliminary 2020 Financial Results
Jan 11, 2021 07:00AM Horizon Therapeutics plc Provides Preliminary 2020 Financial Results, Exceeding Full-Year 2020 Net Sales and Adjusted EBITDA Guidance; Provides Update on TEPEZZA® (teprotumumab-trbw) Supply and New K
Dec 22, 2020 08:00AM Horizon Therapeutics plc to Present at the 39th Annual J.P. Morgan Healthcare Conference
Dec 17, 2020 06:40AM Horizon Therapeutics plc Announces Short-Term TEPEZZA® (teprotumumab-trbw) Supply Disruption Due to Government-Mandated (Operation Warp Speed) COVID-19 Vaccine Production
Dec 3, 2020 09:00AM Horizon Therapeutics plc Provides $1 Million in Scholarships to Help Economically Disadvantaged Students and Students of Color Further Their Liberal Arts and Health Professions Education
Dec 2, 2020 09:15AM Great Place to Work Names Horizon Therapeutics plc to Best Workplaces for Parents List
Nov 30, 2020 08:00AM Horizon Therapeutics plc Donates Additional $1.2 Million to Support COVID-19 Relief Efforts in Illinois and Other Impacted U.S. and International Communities
Nov 25, 2020 08:00AM Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
Nov 23, 2020 08:05AM Horizon Therapeutics (HZNP) and Halozyme Therapeutics (HALO) Enter Global Collaboration and License Agreement for ENHANZE® Technology
Nov 23, 2020 08:00AM Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology
Nov 23, 2020 08:00AM Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology
Nov 17, 2020 09:15AM National Association for Business Resources Names Horizon Therapeutics One of the Best and Brightest Companies to Work For in the Nation
Nov 16, 2020 08:00AM First Thyroid Eye Disease (TED) Awareness Week to Increase Education and Understanding of Vision-Threatening Disease
Nov 13, 2020 08:34AM Horizon Therapeutics (HZNP) Reports New TEPEZZA (teprotumumab-trbw) Data Presented at AAO 2020 Virtual
Nov 13, 2020 08:30AM New Data Build on Growing Evidence Supporting TEPEZZA® (teprotumumab-trbw) Efficacy in Thyroid Eye Disease (TED), Including in Patients With Less Severe Disease and Longer Disease Duration
Nov 13, 2020 08:00AM Horizon Therapeutics plc CEO Tim Walbert Honored with RARE Champion Award at Global Genes Champions of Hope Gala
Nov 12, 2020 08:00AM Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
Nov 2, 2020 02:00PM Horizon Therapeutics (HZNP) Higher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA Concomitantly Used with the Immunomodulator Mycophenolate Mofetil
Nov 2, 2020 02:00PM Higher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA® (pegloticase injection) Concomitantly Used with the Immunomodulator Mycophenolate Mofetil
Nov 2, 2020 07:00AM Horizon Therapeutics plc Reports Record Third-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $800 Million; Increases Full-Year 2020 Net Sales and Adjusted EBITD
Nov 2, 2020 06:58AM Horizon Therapeutics plc Names Karin Rosén, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer
Oct 30, 2020 09:15AM Chicago Tribune Names Horizon Therapeutics a 2020 Top Workplace for the Sixth Consecutive Year
Oct 30, 2020 08:00AM New TEPEZZA® (teprotumumab-trbw) Data to Be Presented at the American Academy of Ophthalmology 2020 Annual Meeting
Oct 29, 2020 08:00AM Horizon Therapeutics plc Initiates Clinical Trial to Assess Shorter Infusion Duration for KRYSTEXXA® (pegloticase injection) Concomitantly Used with Methotrexate to Treat Uncontrolled Gout
Oct 26, 2020 08:00AM Horizon Therapeutics plc Named One of the Most Innovative Companies by Crain’s Chicago Business
Oct 23, 2020 08:00AM Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption
Oct 22, 2020 10:00AM New Data Offers Insights on Treatment with KRYSTEXXA® (pegloticase injection) Among Kidney Transplant Patients for the Management of Uncontrolled Gout
Oct 20, 2020 08:00AM Horizon Therapeutics plc Announces TEPEZZA® (teprotumumab-trbw) Selected as a Winner of the Chicago Innovation Award
Oct 16, 2020 08:30AM FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Medium Workplaces List for Fifth Consecutive Year
Oct 14, 2020 08:03AM Horizon Therapeutics (HZNP) Reports TEPEZZA (teprotumumab-trbw) Data from Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease
Oct 14, 2020 08:00AM TEPEZZA® (teprotumumab-trbw) Data from the Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED)
Oct 8, 2020 08:15AM New Data Evaluating KRYSTEXXA® (pegloticase injection) With Concomitant Immunomodulation to Be Presented at the American College of Rheumatology Convergence 2020
Oct 8, 2020 08:00AM Horizon Therapeutics plc to Release Third-Quarter 2020 Financial Results and Host Webcast on Nov. 2, 2020
Oct 7, 2020 08:00AM Horizon Therapeutics plc Named One of San Francisco Bay Area’s Best and Brightest Companies to Work For
Oct 5, 2020 08:00AM Horizon Therapeutics plc Announces TEPEZZA® (teprotumumab-trbw) Selected as a Winner of the R&D 100 Award
Oct 1, 2020 04:00PM Horizon Therapeutics plc Named as an Angels in Adoption® Honoree by U.S. Congressional Coalition on Adoption for #RAREis Adoption Fund partnership with Gift of Adoption
Sep 16, 2020 08:09AM Horizon Therapeutics (HZNP) MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79% of Patients Achieved Complete Response Using KRYSTEXXA with Methotrexate
Sep 16, 2020 08:00AM MIRROR Open-Label Trial Data Published in Journal of Rheumatology Show 79 Percent of Patients Achieved a Complete Response Using KRYSTEXXA® (pegloticase injection) with Methotrexate
Sep 2, 2020 09:00AM Horizon Therapeutics plc Named to the 2020 PEOPLE “50 Companies That Care” List
Sep 1, 2020 08:00AM Horizon Therapeutics plc to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
Aug 10, 2020 09:00AM Horizon Therapeutics Named one of the Best Places to Work in Chicago by Crain’s Chicago Business
View More Recent Stories View Older Stories